ERBB2 and breast cancer: These results were unexpected since improved pCR rates had been achieved previously in the TBCRC 006 study of women with locally advanced HER2+ and ER+ breast cancer who were treated with neoadjuvant trastuzumab, lapatinib, and letrozole [14].